12/3
07:02 am
tbph
Theravance Biopharma (NASDAQ:TBPH) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.
Low
Report
Theravance Biopharma (NASDAQ:TBPH) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.
11/26
08:05 am
tbph
Theravance Biopharma (NASDAQ:TBPH) had its price target raised by analysts at BTIG Research from $25.00 to $40.00. They now have a "buy" rating on the stock.
Medium
Report
Theravance Biopharma (NASDAQ:TBPH) had its price target raised by analysts at BTIG Research from $25.00 to $40.00. They now have a "buy" rating on the stock.
11/23
02:11 am
tbph
Theravance Biopharma (NASDAQ:TBPH) was upgraded by analysts at
Wall Stre
Low
Report
Theravance Biopharma (NASDAQ:TBPH) was upgraded by analysts at
Wall Stre
11/20
11:36 am
tbph
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 [Yahoo! Finance]
Low
Report
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 [Yahoo! Finance]
11/20
11:00 am
tbph
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025
Low
Report
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025
11/19
06:42 am
tbph
Theravance Biopharma to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Theravance Biopharma to Participate in Upcoming Investor Conferences [Yahoo! Finance]
11/19
06:00 am
tbph
Theravance Biopharma to Participate in Upcoming Investor Conferences
Medium
Report
Theravance Biopharma to Participate in Upcoming Investor Conferences
11/13
02:20 am
tbph
Here's Why Shares in Theravance Biopharma Exploded Today [Yahoo! Finance]
Low
Report
Here's Why Shares in Theravance Biopharma Exploded Today [Yahoo! Finance]
11/11
08:09 am
tbph
Theravance Biopharma (NASDAQ:TBPH) had its price target raised by analysts at HC Wainwright from $15.00 to $20.00. They now have a "buy" rating on the stock.
High
Report
Theravance Biopharma (NASDAQ:TBPH) had its price target raised by analysts at HC Wainwright from $15.00 to $20.00. They now have a "buy" rating on the stock.
11/11
04:06 am
tbph
Theravance Biopharma, Inc. (TBPH) Q3 2025 Earnings Call Transcript [Seeking Alpha]
High
Report
Theravance Biopharma, Inc. (TBPH) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/10
04:32 pm
tbph
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/10
04:17 pm
tbph
Theravance Biopharma GAAP EPS of $0.07 beats by $0.20, revenue of $19.99M beats by $0.1M [Seeking Alpha]
High
Report
Theravance Biopharma GAAP EPS of $0.07 beats by $0.20, revenue of $19.99M beats by $0.1M [Seeking Alpha]
11/10
04:05 pm
tbph
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
High
Report
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/29
06:00 am
tbph
Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System
Low
Report
Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System
10/27
06:00 am
tbph
Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025
Low
Report
Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025
10/25
12:13 pm
tbph
Theravance Biopharma (NASDAQ:TBPH) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Theravance Biopharma (NASDAQ:TBPH) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
10/16
08:05 am
tbph
Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy
Medium
Report
Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy
10/14
06:22 am
tbph
Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting [Yahoo! Finance]
Low
Report
Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting [Yahoo! Finance]
10/14
06:00 am
tbph
Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting
Low
Report
Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting
9/21
07:23 am
tbph
How Recent Developments Are Changing the Theravance Biopharma Investment Story [Yahoo! Finance]
Medium
Report
How Recent Developments Are Changing the Theravance Biopharma Investment Story [Yahoo! Finance]
9/17
06:43 am
tbph
Theravance Biopharma (NASDAQ:TBPH) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Theravance Biopharma (NASDAQ:TBPH) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
9/13
05:50 am
tbph
Theravance Biopharma (NASDAQ:TBPH) was upgraded by analysts at B. Riley to a "strong-buy" rating.
Low
Report
Theravance Biopharma (NASDAQ:TBPH) was upgraded by analysts at B. Riley to a "strong-buy" rating.
9/12
08:03 am
tbph
Theravance Biopharma (NASDAQ:TBPH) is now covered by analysts at B. Riley. They set a "buy" rating and a $28.00 price target on the stock.
Low
Report
Theravance Biopharma (NASDAQ:TBPH) is now covered by analysts at B. Riley. They set a "buy" rating and a $28.00 price target on the stock.